683 related articles for article (PubMed ID: 17213019)
21. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
22. Peripheral neuroblastic tumours in eastern Denmark 1972-2002.
Zimling ZG; Rechnitzer C; Rasmussen M; Petersen BL
APMIS; 2007 Jan; 115(1):66-74. PubMed ID: 17223852
[TBL] [Abstract][Full Text] [Related]
23. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
[TBL] [Abstract][Full Text] [Related]
24. Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan.
Kaneko Y; Kobayashi H; Watanabe N; Tomioka N; Nakagawara A
Pediatr Blood Cancer; 2006 Mar; 46(3):285-91. PubMed ID: 16078225
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
26. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma.
Komuro H; Valentine MB; Rowe ST; Kidd VJ; Makino S; Brodeur GM; Cohn SL; Look AT
J Pediatr Surg; 1998 Nov; 33(11):1695-8. PubMed ID: 9856898
[TBL] [Abstract][Full Text] [Related]
28. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
[TBL] [Abstract][Full Text] [Related]
29. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
[TBL] [Abstract][Full Text] [Related]
30. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
31. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
Wan TS; Ma ES; Chan GC; Chan LC
Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
[TBL] [Abstract][Full Text] [Related]
32. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
33. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
[TBL] [Abstract][Full Text] [Related]
34. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
35. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
[TBL] [Abstract][Full Text] [Related]
36. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
37. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
38. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
[TBL] [Abstract][Full Text] [Related]
39. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content.
Piqueras M; Navarro S; Cañete A; Castel V; Noguera R
Histopathology; 2011 Jul; 59(1):22-30. PubMed ID: 21668478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
